氟伐他汀降低肾移植和经皮冠状动脉介入治疗患者的主要不良心脏事件风险的研究进展

Research Progress of Fluvastatin in Reducing the Risk of Major Adverse Cardiac Events in Renal Transplant Recipients and PCI Patients

对肾移植患者和首次接受经皮冠状动脉介入治疗成功后的患者,应用氟伐他汀治疗可显著降低其发生主要不良心脏事件的风险。本文将综述氟伐他汀降低肾移植和经皮冠状动脉介入治疗患者的主要不良心脏事件的研究进展。

Fluvastatin treatment in renal transplant recipients and patients following successful first percutaneous coronary intervention(PCI)significantly reduces the risk of major adverse cardiac events(MACE).This review summarizes the research progress on fluvastatin in reducing the risk of MACE in renal transplant recipients and PCI patients.